OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study
George A. Fisher, Edward M. Wolin, Nilani Liyanage, et al.
The Oncologist (2017) Vol. 23, Iss. 1, pp. 16-24
Open Access | Times Cited: 26
George A. Fisher, Edward M. Wolin, Nilani Liyanage, et al.
The Oncologist (2017) Vol. 23, Iss. 1, pp. 16-24
Open Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
James C. Yao, Emily K. Bergsland, Rahul Aggarwal, et al.
The Oncologist (2022) Vol. 27, Iss. 11, pp. 940-951
Open Access | Times Cited: 47
James C. Yao, Emily K. Bergsland, Rahul Aggarwal, et al.
The Oncologist (2022) Vol. 27, Iss. 11, pp. 940-951
Open Access | Times Cited: 47
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Jennifer R. Eads, Þorvarður R. Hálfdánarson, Tim Asmis, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 8
Open Access | Times Cited: 19
Jennifer R. Eads, Þorvarður R. Hálfdánarson, Tim Asmis, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 8
Open Access | Times Cited: 19
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives
Roberta Modica, Alessia Liccardi, Roberto Minotta, et al.
Expert Review of Endocrinology & Metabolism (2022) Vol. 17, Iss. 5, pp. 389-403
Closed Access | Times Cited: 24
Roberta Modica, Alessia Liccardi, Roberto Minotta, et al.
Expert Review of Endocrinology & Metabolism (2022) Vol. 17, Iss. 5, pp. 389-403
Closed Access | Times Cited: 24
Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours
Tim Meyer, Martyn Caplin, Mohid S. Khan, et al.
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 4
Open Access | Times Cited: 15
Tim Meyer, Martyn Caplin, Mohid S. Khan, et al.
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 4
Open Access | Times Cited: 15
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 3
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 3
Quality of life in patients with midgut NET following peptide receptor radionuclide therapy
Milka Marinova, Martin Mücke, Felix Fischer, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 46, Iss. 11, pp. 2252-2259
Closed Access | Times Cited: 24
Milka Marinova, Martin Mücke, Felix Fischer, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 46, Iss. 11, pp. 2252-2259
Closed Access | Times Cited: 24
Sex differences in carcinoid syndrome: A gap to be closed
Rosaria Maddalena Ruggeri, Barbara Altieri, Erika Grossrubatcher, et al.
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 3, pp. 659-669
Closed Access | Times Cited: 13
Rosaria Maddalena Ruggeri, Barbara Altieri, Erika Grossrubatcher, et al.
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 3, pp. 659-669
Closed Access | Times Cited: 13
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
Rosario Pivonello, Pamela N. Münster, Massimo Terzolo, et al.
Frontiers in Endocrinology (2022) Vol. 12
Open Access | Times Cited: 12
Rosario Pivonello, Pamela N. Münster, Massimo Terzolo, et al.
Frontiers in Endocrinology (2022) Vol. 12
Open Access | Times Cited: 12
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care
Jaydira Del Rivero, Josh Mailman, Michael W. Rabow, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 7
Open Access | Times Cited: 6
Jaydira Del Rivero, Josh Mailman, Michael W. Rabow, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 7
Open Access | Times Cited: 6
Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
Sara Pusceddu, Roberta Rossi, Martina Torchio, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 8, pp. 2468-2468
Open Access | Times Cited: 16
Sara Pusceddu, Roberta Rossi, Martina Torchio, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 8, pp. 2468-2468
Open Access | Times Cited: 16
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis
Martin A. Walter, Cédric Nesti, Marko Spanjol, et al.
Cochrane library (2021) Vol. 2021, Iss. 11
Open Access | Times Cited: 11
Martin A. Walter, Cédric Nesti, Marko Spanjol, et al.
Cochrane library (2021) Vol. 2021, Iss. 11
Open Access | Times Cited: 11
Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis
Jessica Maxwell, Boris G. Naraev, Daniel M. Halperin, et al.
Annals of Surgical Oncology (2022) Vol. 29, Iss. 5, pp. 3072-3084
Open Access | Times Cited: 7
Jessica Maxwell, Boris G. Naraev, Daniel M. Halperin, et al.
Annals of Surgical Oncology (2022) Vol. 29, Iss. 5, pp. 3072-3084
Open Access | Times Cited: 7
PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK
Mohid S. Khan, Kathryn Cook, Martin O. Weickert, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 3
Open Access | Times Cited: 1
Mohid S. Khan, Kathryn Cook, Martin O. Weickert, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 3
Open Access | Times Cited: 1
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives
E Lauricella, Sofija Vilisova, Nada Chaoul, et al.
Expert Review of Neurotherapeutics (2024), pp. 1-14
Closed Access | Times Cited: 1
E Lauricella, Sofija Vilisova, Nada Chaoul, et al.
Expert Review of Neurotherapeutics (2024), pp. 1-14
Closed Access | Times Cited: 1
Biochemical Responses in Symptomatic and Asymptomatic Patients with Neuroendocrine Tumors: Pooled Analysis of Two Phase 3 Trials
Beloo Mirakhur, Marianne Pavel, Rodney F. Pommier, et al.
Endocrine Practice (2018) Vol. 24, Iss. 11, pp. 948-962
Open Access | Times Cited: 10
Beloo Mirakhur, Marianne Pavel, Rodney F. Pommier, et al.
Endocrine Practice (2018) Vol. 24, Iss. 11, pp. 948-962
Open Access | Times Cited: 10
Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review
Anna La Salvia, Alberto Portigliatti Pomeri, Irene Persano, et al.
Comprehensive Psychiatry (2021) Vol. 109, pp. 152244-152244
Open Access | Times Cited: 8
Anna La Salvia, Alberto Portigliatti Pomeri, Irene Persano, et al.
Comprehensive Psychiatry (2021) Vol. 109, pp. 152244-152244
Open Access | Times Cited: 8
Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
Sheila D. Rustgi, Aaron Oh, Jeong Yun Yang, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 8
Sheila D. Rustgi, Aaron Oh, Jeong Yun Yang, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 8
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues
Lowell Anthony, Thomas M. O’Dorisio
The Oncologist (2021) Vol. 26, Iss. 7, pp. e1171-e1178
Open Access | Times Cited: 5
Lowell Anthony, Thomas M. O’Dorisio
The Oncologist (2021) Vol. 26, Iss. 7, pp. e1171-e1178
Open Access | Times Cited: 5
<p>A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial</p>
K Blot, Luc Duchateau, Bénédicte Lescrauwaet, et al.
Patient Related Outcome Measures (2019) Vol. Volume 10, pp. 335-343
Open Access | Times Cited: 4
K Blot, Luc Duchateau, Bénédicte Lescrauwaet, et al.
Patient Related Outcome Measures (2019) Vol. Volume 10, pp. 335-343
Open Access | Times Cited: 4
Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study
Lionel Duck, Gauthier Demolin, Lionel D’Hondt, et al.
Clinical Therapeutics (2021) Vol. 43, Iss. 12, pp. 2136-2145.e2
Open Access | Times Cited: 3
Lionel Duck, Gauthier Demolin, Lionel D’Hondt, et al.
Clinical Therapeutics (2021) Vol. 43, Iss. 12, pp. 2136-2145.e2
Open Access | Times Cited: 3
Optimizing the Management of Carcinoid Syndrome to Reduce the Impact of Diarrhea
Rory Randall, Bonita Bennett, Tiffany Valone, et al.
Journal of the Advanced Practitioner in Oncology (2019) Vol. 10, Iss. 8
Open Access | Times Cited: 2
Rory Randall, Bonita Bennett, Tiffany Valone, et al.
Journal of the Advanced Practitioner in Oncology (2019) Vol. 10, Iss. 8
Open Access | Times Cited: 2
Tumores neuroendocrinos
Eider Pascual‐Corrales, Marta Araujo‐Castro, A.E. Ortiz-Flores, et al.
Medicine - Programa de Formación Médica Continuada Acreditado (2020) Vol. 13, Iss. 18, pp. 1019-1028
Closed Access | Times Cited: 2
Eider Pascual‐Corrales, Marta Araujo‐Castro, A.E. Ortiz-Flores, et al.
Medicine - Programa de Formación Médica Continuada Acreditado (2020) Vol. 13, Iss. 18, pp. 1019-1028
Closed Access | Times Cited: 2
Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa
Daleen Geldenhuys, Bernardo L. Rapoport, Samuel Fourie, et al.
South African Journal of Oncology (2020) Vol. 4
Open Access
Daleen Geldenhuys, Bernardo L. Rapoport, Samuel Fourie, et al.
South African Journal of Oncology (2020) Vol. 4
Open Access
PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK
Mohid S. Khan, Louise Davies, Melissa Back, et al.
Endocrine Abstracts (2022)
Open Access
Mohid S. Khan, Louise Davies, Melissa Back, et al.
Endocrine Abstracts (2022)
Open Access
The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials
Aimee R. Hayes, David L. Chan, Bryan Chan, et al.
Journal of Neuroendocrinology (2021) Vol. 33, Iss. 9
Closed Access
Aimee R. Hayes, David L. Chan, Bryan Chan, et al.
Journal of Neuroendocrinology (2021) Vol. 33, Iss. 9
Closed Access
